Literature DB >> 14706940

Comparison of progressive cortical gray matter loss in childhood-onset schizophrenia with that in childhood-onset atypical psychoses.

Nitin Gogtay1, Alexandra Sporn, Liv S Clasen, Tom F Nugent, Deanna Greenstein, Rob Nicolson, Jay N Giedd, Marge Lenane, Pete Gochman, Alan Evans, Judith L Rapoport.   

Abstract

BACKGROUND: Recent anatomical brain magnetic resonance imaging (MRI) studies show a striking postpsychotic progressive loss of cortical gray matter (GM) in patients with childhood-onset schizophrenia (COS), which appears greater than that seen for adult patients. However, the diagnostic specificity and the relationship of these changes to drug treatment and cognitive functioning remain unclear. We performed a comparative prospective brain MRI study in patients with COS and pediatric patients with transient psychosis with behavior problems (psychosis not otherwise specified) provisionally considered multidimensionally impaired (MDI). We hypothesized that cortical GM loss would occur in patients with COS but not in adolescents with atypical psychoses.
METHODS: Anatomical brain MRI was performed at baseline and follow-up in 19 patients in the MDI group (mean [SD] age of 13.3 [3.1] years); in 23 patients with COS matched for age, sex, IQ score, and drug treatment (mean [SD] age of 13.9 [2.5] years); and 38 healthy control subjects matched for age and sex (mean [SD] age of 13.3 [3.1] years). The mean (SD) follow-up was 2.5 (0.8) years. Volumes of the cerebrum and total and regional GM were obtained by using automated analysis, and percent change in volume across time was calculated. One-way analyses of variance with post hoc Tukey Honestly Significantly Different comparisons were performed to examine group differences in the percent change in GM across follow-up.
RESULTS: The COS group had significantly greater total, frontal, temporal, and parietal GM loss than did the MDI or healthy control groups; analysis of variance post hoc P values ranged from.03 to.001. The MDI and control groups did not differ significantly from each other.
CONCLUSIONS: The cortical GM volume loss in COS appears diagnostically specific; it was not seen in children and adolescents with atypical psychosis. Because both patient groups had similar early developmental patterns, cognitive functioning, medications, and hospitalizations, this progressive loss appears to be intrinsic to COS. An ongoing neurodevelopmental process and/or brain response specific to the illness could account for these changes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706940     DOI: 10.1001/archpsyc.61.1.17

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  50 in total

1.  White matter integrity, language, and childhood onset schizophrenia.

Authors:  Kristi Clark; Katherine L Narr; Joseph O'Neill; Jennifer Levitt; Prabha Siddarth; Owen Phillips; Arthur Toga; Rochelle Caplan
Journal:  Schizophr Res       Date:  2012-03-10       Impact factor: 4.939

2.  Multicenter study of brain volume abnormalities in children and adolescent-onset psychosis.

Authors:  Santiago Reig; Mara Parellada; Josefina Castro-Fornieles; Joost Janssen; Dolores Moreno; Inmaculada Baeza; Nuria Bargalló; Ana González-Pinto; Montserrat Graell; Felipe Ortuño; Soraya Otero; Celso Arango; Manuel Desco
Journal:  Schizophr Bull       Date:  2010-05-16       Impact factor: 9.306

Review 3.  Viewing the Personality Traits Through a Cerebellar Lens: a Focus on the Constructs of Novelty Seeking, Harm Avoidance, and Alexithymia.

Authors:  Laura Petrosini; Debora Cutuli; Eleonora Picerni; Daniela Laricchiuta
Journal:  Cerebellum       Date:  2017-02       Impact factor: 3.847

4.  Visual Cortical Alterations and their Association with Negative Symptoms in Antipsychotic-Naïve First Episode Psychosis.

Authors:  Iniya Adhan; Paulo Lizano; Deepthi Bannai; Olivia Lutz; Kiranpreet Dhaliwal; Victor Zeng; Jean Miewald; Debra Montrose; Matcheri Keshavan
Journal:  Psychiatry Res       Date:  2020-04-16       Impact factor: 3.222

5.  Childhood onset schizophrenia and early onset schizophrenia spectrum disorders.

Authors:  David I Driver; Nitin Gogtay; Judith L Rapoport
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2013-06-18

6.  Accelerated brain aging in schizophrenia and beyond: a neuroanatomical marker of psychiatric disorders.

Authors:  Nikolaos Koutsouleris; Christos Davatzikos; Stefan Borgwardt; Christian Gaser; Ronald Bottlender; Thomas Frodl; Peter Falkai; Anita Riecher-Rössler; Hans-Jürgen Möller; Maximilian Reiser; Christos Pantelis; Eva Meisenzahl
Journal:  Schizophr Bull       Date:  2013-10-13       Impact factor: 9.306

7.  Lack of gender influence on cortical and subcortical gray matter development in childhood-onset schizophrenia.

Authors:  Brian Weisinger; Deanna Greenstein; Anand Mattai; Liv Clasen; Francois Lalonde; Sara Feldman; Rachel Miller; Julia W Tossell; Nora S Vyas; Reva Stidd; Christopher David; Nitin Gogtay
Journal:  Schizophr Bull       Date:  2011-05-25       Impact factor: 9.306

8.  Linking novelty seeking and harm avoidance personality traits to cerebellar volumes.

Authors:  Daniela Laricchiuta; Laura Petrosini; Fabrizio Piras; Enrica Macci; Debora Cutuli; Chiara Chiapponi; Antonio Cerasa; Eleonora Picerni; Carlo Caltagirone; Paolo Girardi; Stefano Maria Tamorri; Gianfranco Spalletta
Journal:  Hum Brain Mapp       Date:  2012-09-11       Impact factor: 5.038

Review 9.  Executive function, adherence, and glycemic control in adolescents with type 1 diabetes: a literature review.

Authors:  Danny C Duke; Michael A Harris
Journal:  Curr Diab Rep       Date:  2014-10       Impact factor: 4.810

10.  Voxel-based structural magnetic resonance imaging (MRI) study of patients with early onset schizophrenia.

Authors:  Yujiro Yoshihara; Genichi Sugihara; Hideo Matsumoto; John Suckling; Katsuhiko Nishimura; Takao Toyoda; Haruo Isoda; Kenji J Tsuchiya; Kiyokazu Takebayashi; Katsuaki Suzuki; Harumi Sakahara; Kazuhiko Nakamura; Norio Mori; Nori Takei
Journal:  Ann Gen Psychiatry       Date:  2008-12-22       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.